Dr Reddys

Dr Reddys News

Indian Markets Rebound Sharply as Dr. Reddy's Soars 7% on USFDA Clearance and Earnings Beat

India's Nifty 50 recovered 1.2% in afternoon trading, with Dr. Reddy's Laboratories (+7%) leading the pharma rally.

Oct 26, 2026

Dr Reddy's Q2 Profit Falls on Lenalidomide Exclusivity Cliff but Beats Estimates

Dr Reddy's Laboratories reported a net profit decline driven by lower Lenalidomide sales as generic exclusivity eroded, but the company beat analyst estimates, limiting stock downside.

Oct 24, 2026

🇮🇳 India

Dr Reddy's Crashes 9% on Q1 FY27 Miss: Semaglutide Costs and US Generic Erosion Create 2-Quarter Earnings Trough

Dr Reddy's shares crashed nearly 9% on Q1 FY27 miss driven by semaglutide API ramp costs and US generic price erosion; three brokerages turned bearish as analysts project a 2-3 quarter earnings trough before GLP-1 bet matures.

Jul 24, 2026

🇮🇳 India

Dr Reddy's Plunges 9% as Semaglutide API Costs and US Generic Erosion Crush Margins

Dr Reddy's shares fell 9% Thursday after Q1 FY27 results showed margin pressure from semaglutide API manufacturing ramp costs and US generic pricing erosion, with bearish brokerages flagging further downside risk.

Jul 24, 2026